Annals of Emergency Medicine
Volume 50, Issue 3 , Pages 335-345.e2 , September 2007

Prevention of Contrast-Induced Nephropathy in the Emergency Department

  • Richard Sinert, DO

      Affiliations

    • Corresponding Author InformationAddress for correspondence: Richard Sinert, DO, Department of Emergency Medicine, Box 1228, SUNY–Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203; 718-245-2973, fax 718-245-4799
    • ,
  • Christopher I. Doty, MD

Received 25 August 2006 ,Revised 13 January 2007 ,Accepted 26 January 2007.

References 

  1. Wyer PC, Rowe BH, Guyatt GH, et al. Evidence-based emergency medicine (The clinician and the medical literature: when can we take a shortcut?). Ann Emerg Med. 2000;36:149–155
  2. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368–375
  3. Barrett BJ, Parfrey PS. Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med. 1994;331:1449–1450
  4. Barrett BJ, Parfrey PS. Clinical practice (Preventing nephropathy induced by contrast medium). N Engl J Med. 2006;354:379–386
  5. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542–1548
  6. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44:1780–1785
  7. Davidson CJ, Hlatky M, Morris KG, et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization (A prospective trial). Ann Intern Med. 1989;110:119–124
  8. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259–2264
  9. Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol. 2004;94:300–305
  10. Alamartine E, Phayphet M, Thibaudin D, et al. Contrast medium-induced acute renal failure and cholesterol embolism after radiological procedures: incidence, risk factors, and compliance with recommendations. Eur J Intern Med. 2003;14:426–431
  11. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and theophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol. 1999;83:260–263
  12. Kapoor A, Sinha N, Sharma RK, et al. Use of dopamine in prevention of contrast induced acute renal failure—a randomised study. Int J Cardiol. 1996;53:233–236
  13. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA. 2003;290:2284–2291
  14. Tumlin JA, Wang A, Murray PT, et al. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J. 2002;143:894–903
  15. Khoury Z, Schlicht JR, Como J, et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy. 1995;15:59–65
  16. Spangberg-Viklund B, Berglund J, Nikonoff T, et al. Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function?. Scand J Urol Nephrol. 1996;30:63–68
  17. Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron. 1992;62:413–415
  18. Kurnik BR, Weisberg LS, Cuttler IM, et al. Effects of atrial natriuretic peptide versus mannitol on renal blood flow during radiocontrast infusion in chronic renal failure. J Lab Clin Med. 1990;116:27–36
  19. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491
  20. Sackner-Bernstein JD, Kowalski M, Fox M, et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900–1905
  21. Wang A, Holcslaw T, Bashore TM, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int. 2000;57:1675–1680
  22. Miller HI, Dascalu A, Rassin TA, et al. Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure: a randomized, parallel, double-blind clinical trial. Am J Nephrol. 2003;23:91–95
  23. Koch JA, Plum J, Grabensee B, et al. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? (PGE1 Study Group). Nephrol Dial Transplant. 2000;15:43–49
  24. Ochoa A, Pellizzon G, Addala S, et al. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. J Interv Cardiol. 2004;17:159–165
  25. Baker CS, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41:2114–2118
  26. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62:2202–2207
  27. Huber W, Schipek C, Ilgmann K, et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol. 2003;91:1157–1162
  28. Huber W, Ilgmann K, Page M, et al. Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology. 2002;223:772–779
  29. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291:2328–2334
  30. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110:2837–2842
  31. Jacobs DS, De Mott WR, Strobel SL, et al. Chemistry. In:  Jacobs DS,  Kasten BL,  De Mott WR, et al. editor. Laboratory Test Handbook. Baltimore, MD: Williams & Wilkins; 1990;p. 171–172
  32. Dzgoeva FU, Milovanov Iu S, Kutyrina IM. Acute kidney failure related to the use of x-ray contrast agents and indomethacin: the risk factors and mechanisms of its development. Ter Arkh. 1995;67:36–39
  33. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet (A randomized, controlled trial). Ann Intern Med. 2000;133:1–9
  34. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416–1420
  35. Temple RJ. A regulatory authority’s opinion about surrogate endpoints. In:  Nimmo WS,  Tucker GT editor. Clinical Measurement in Drug Evaluation. New York, NY: Wiley; 1995;
  36. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med. 1996;125:605–613
  37. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39:930–936
  38. Madyoon H, Croushore L, Weaver D, et al. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv. 2001;53:341–345
  39. Harris KG, Smith TP, Cragg AH, et al. Nephrotoxicity from contrast material in renal insufficiency: ionic versus nonionic agents. Radiology. 1991;179:849–852
  40. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491–499
  41. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality (A cohort analysis). JAMA. 1996;275:1489–1494
  42. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773–2782
  43. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393–1399
  44. Mueller C. Prevention of contrast-induced nephropathy with volume supplementation [review]. Kidney Int Suppl. 2006;100:S16–S19

 Supervising editor: Peter C. Wyer, MDFunding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article, that may create any potential conflict of interest. The authors have stated that no such relationships exist. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement.Available online May 21, 2007.Reprints not available from the authors.

PII: S0196-0644(07)00121-7

doi: 10.1016/j.annemergmed.2007.01.023

Annals of Emergency Medicine
Volume 50, Issue 3 , Pages 335-345.e2 , September 2007

Article Tools

* Image Usage & Resolution